Arie Zask

4.4k total citations
77 papers, 3.2k citations indexed

About

Arie Zask is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Arie Zask has authored 77 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Molecular Biology, 25 papers in Organic Chemistry and 13 papers in Oncology. Recurrent topics in Arie Zask's work include PI3K/AKT/mTOR signaling in cancer (22 papers), Ubiquitin and proteasome pathways (12 papers) and Protein Kinase Regulation and GTPase Signaling (10 papers). Arie Zask is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (22 papers), Ubiquitin and proteasome pathways (12 papers) and Protein Kinase Regulation and GTPase Signaling (10 papers). Arie Zask collaborates with scholars based in United States, Canada and Switzerland. Arie Zask's co-authors include Ker Yu, Jeroen C. Verheijen, George A. Ellestad, Lourdes Toral‐Barza, Semiramis Ayral‐Kaloustian, Joshua A. Kaplan, John D. Murphy, Kevin J. Curran, M. F. SEMMELHACK and Judy Lucas and has published in prestigious journals such as Cell, Journal of the American Chemical Society and Nature Communications.

In The Last Decade

Arie Zask

76 papers receiving 3.1k citations

Peers

Countries citing papers authored by Arie Zask

Since Specialization

Citations

This map shows the geographic impact of Arie Zask's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arie Zask with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arie Zask more than expected).

Fields of papers citing papers by Arie Zask

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arie Zask. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arie Zask. The network helps show where Arie Zask may publish in the future.

Co-authorship network of co-authors of Arie Zask

This figure shows the co-authorship network connecting the top 25 collaborators of Arie Zask. A scholar is included among the top collaborators of Arie Zask based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arie Zask. Arie Zask is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening 2025 ·Nature Communications ·Hengrui Liu, Arie Zask, F. Forouhar, Sho Iketani, (unknown), (unknown), (unknown), Kwan Sam Choi, (unknown), Seo Jung Hong, David H. Lovett, Tian Bai, Alejandro Chavez, David D. Ho, Brent R. Stockwell	1
2	Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers 2023 ·Cell chemical biology ·Michael E. Stokes, Alessandro Vasciaveo, (unknown), Arie Zask, Eduard Reznik, (unknown), Qian Wang, (unknown), F. Forouhar, Presha Rajbhandari, Andrea Califano, Brent R. Stockwell	4
3	Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia 2022 ·Cancer Discovery ·Clara Reglero, Chelsea L. Dieck, Arie Zask, F. Forouhar, (unknown), Wen-Hsuan W. Lin, (unknown), (unknown), (unknown), Julie M. Gastier‐Foster, Mignon L. Loh, Liang Tong, Brent R. Stockwell, Teresa Palomero, Adolfo A. Ferrando	6
4	Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors 2021 ·Nature Communications ·Sho Iketani, F. Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S. Nair, Arie Zask, Yaoxing Huang, Xing Li, Brent R. Stockwell, Alejandro Chavez, David D. Ho	8
5	Reflections on the intriguing occurrence of some recently isolated natural products as racemates and scalemic mixtures 2021 ·Chirality ·Arie Zask, George A. Ellestad	9
6	Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors 2021 ·Nature Communications ·Sho Iketani, F. Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Manoj S. Nair, Arie Zask, Yaoxing Huang, Xing Li, Brent R. Stockwell, Alejandro Chavez, David D. Ho	79
7	The enduring legacy of Koji Nakanishi's research on bioorganic chemistry and natural products. Part 1: Isolation, structure determination and mode of action 2020 ·Chirality ·George A. Ellestad, Arie Zask, Nina Berova	1
8	Biomimetic syntheses of racemic natural products 2017 ·Chirality ·Arie Zask, George A. Ellestad	28
9	Multivalent Small-Molecule Pan-RAS Inhibitors 2017 ·Cell ·Matthew Welsch, Anna Kaplan, Jennifer M. Chambers, Michael E. Stokes, Pieter H. Bos, Arie Zask, Yan Zhang, Marta Sánchez-Martín, Michael A. Badgley, Christine Huang, Timothy H. Tran, Hemanth Akkiraju, Lewis M. Brown, Renu Nandakumar, Serge Cremers, Wan Seok Yang, Liang Tong, Kenneth P. Olive, Adolfo A. Ferrando, Brent R. Stockwell	199
10	Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2 2010 ·Cancer Research ·Ker Yu, Celine Shi, Lourdes Toral‐Barza, Judy Lucas, Boris Shor, (unknown), Weiguo Zhang, Robert Mahoney, (unknown), (unknown), (unknown), (unknown), Kevin J. Curran, Joshua A. Kaplan, Jeroen C. Verheijen, Semiramis Ayral‐Kaloustian, Tarek S. Mansour, Robert T. Abraham, Arie Zask, James J. Gibbons	162
11	2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability 2010 ·Bioorganic & Medicinal Chemistry Letters ·Jeroen C. Verheijen, David J. Richard, Kevin J. Curran, Joshua A. Kaplan, Ker Yu, Arie Zask	22
12	Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent 2010 ·Bioorganic & Medicinal Chemistry Letters ·Kevin J. Curran, Jeroen C. Verheijen, Joshua A. Kaplan, David J. Richard, Lourdes Toral‐Barza, Irwin Hollander, Judy Lucas, Semiramis Ayral‐Kaloustian, Ker Yu, Arie Zask	61
13	Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin 2009 ·Cancer Research ·Ker Yu, Lourdes Toral‐Barza, Celine Shi, Weiguo Zhang, Judy Lucas, Boris Shor, (unknown), Jeroen C. Verheijen, Kevin J. Curran, David J. Malwitz, Derek C. Cole, John W. Ellingboe, Semiramis Ayral‐Kaloustian, Tarek S. Mansour, James J. Gibbons, Robert T. Abraham, Paweł Nowak, Arie Zask	277
14	Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K 2009 ·Bioorganic & Medicinal Chemistry Letters ·Jeroen C. Verheijen, Ker Yu, Lourdes Toral‐Barza, Irwin Hollander, Arie Zask	32
15	Incorporation of water-solubilizing groups in pyrazolopyrimidine mTOR inhibitors: Discovery of highly potent and selective analogs with improved human microsomal stability 2009 ·Bioorganic & Medicinal Chemistry Letters ·David J. Richard, Jeroen C. Verheijen, Kevin J. Curran, Joshua A. Kaplan, Lourdes Toral‐Barza, Irwin Hollander, Judy Lucas, Ker Yu, Arie Zask	42
16	Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors 2005 ·Bioorganic & Medicinal Chemistry Letters ·Arie Zask, Joshua A. Kaplan, Xuemei Du, (unknown), Vincent Sandanayaka, (unknown), Jeremy I. Levin, Guixian Jin, Jun Xu, Terri Cummons, D. Barone, Semiramis Ayral‐Kaloustian, Jerauld S. Skotnicki	23
17	Hemiasterlin analogs exclusively label α-tubulin at the interdimer region and specifically block subtilisin digestion of α-tubulin 2004 ·Cancer Research ·Malathi Hari, Maria Nunes, Arie Zask, Joshua A. Kaplan, Joseph L. Wooters, Albert A. Minnick, (unknown), Sylvia Musto, Carl F. Beyer, Girija Krishnamurthy, Yongchang Qiu, Frank Loganzo, Semiramis Ayral‐Kaloustian, Lee M. Greenberger	1
18	Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in alpha-tubulin. 2004 ·PubMed ·Frank Loganzo, Malathi Hari, Tami Annable, Xingzhi Tan, (unknown), Sylvia Musto, Arie Zask, Joshua A. Kaplan, Albert A. Minnick, (unknown), Semiramis Ayral‐Kaloustian, Marianne S. Poruchynsky, Tito Fojo, Lee M. Greenberger	25
19	Inhibition of Matrix Metalloproteinases: Structure Based Design 1996 ·Current Pharmaceutical Design ·Arie Zask, Jeremy I. Levin, Loran M. Killar, Jerauld S. Skotnicki	63
20	Synthesis and antihyperglycemic activity of novel 5-(naphthalenylsulfonyl)-2,4-thiazolidinediones 1990 ·Journal of Medicinal Chemistry ·Arie Zask, Ivo Jirkovsky, (unknown), Michael L. McCaleb	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact